UCB licenses BioWa's Potelligent Technology for use in antibody research and development
Advertisement
BioWa, Inc. and UCB announced that they have entered into an agreement which provides UCB with access to BioWa's patented POTELLIGENT® technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. The agreement grants UCB non-exclusive rights to research and develop antibodies for an undisclosed number of targets. In return, BioWa will receive license fees, milestone payments and royalties on products developed by UCB. Details of financial terms were not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous